MENU
+Compare
ZNTL
Stock ticker: NASDAQ
AS OF
Sep 5 closing price
Price
$1.75
Change
-$0.02 (-1.13%)
Capitalization
126.24M

ZNTL Zentalis Pharmaceuticals Forecast, Technical & Fundamental Analysis

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC)... Show more

ZNTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ZNTL with price predictions
Sep 04, 2025

ZNTL's RSI Oscillator recovers from overbought zone

The 10-day RSI Indicator for ZNTL moved out of overbought territory on August 25, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 instances where the indicator moved out of the overbought zone. In of the 27 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 48 cases where ZNTL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ZNTL turned negative on September 03, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZNTL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ZNTL broke above its upper Bollinger Band on August 21, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 12, 2025. You may want to consider a long position or call options on ZNTL as a result. In of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

ZNTL moved above its 50-day moving average on August 04, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where ZNTL advanced for three days, in of 279 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 132 cases where ZNTL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.460) is normal, around the industry mean (19.994). P/E Ratio (0.000) is within average values for comparable stocks, (51.700). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.073). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (4.658) is also within normal values, averaging (325.279).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ZNTL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZNTL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
ZNTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

ZNTL is expected to report earnings to rise 42.65% to -52 cents per share on November 03

Zentalis Pharmaceuticals ZNTL Stock Earnings Reports
Q3'25
Est.
$-0.53
Q2'25
Beat
by $0.17
Q1'25
Beat
by $0.01
Q4'24
Beat
by $0.16
Q3'24
Beat
by $0.05
The last earnings report on August 06 showed earnings per share of -37 cents, beating the estimate of -54 cents. With 422.76K shares outstanding, the current market capitalization sits at 126.24M.
A.I. Advisor
published General Information

General Information

a clinical-stage biopharmaceutical company, which focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
1359 Broadway
Phone
+1 212 433-3791
Employees
168
Web
https://www.zentalis.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FINN13020.0015.00
+0.12%
First National of Nebraska, Inc.
BOIRF24.50N/A
N/A
Boiron
WTXR0.07N/A
N/A
West Texas Resources, Inc.
TRATF36.95N/A
N/A
Traton SE
LIMX2.05-0.44
-17.67%
Limitless X Holdings Inc.

ZNTL and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ZNTL has been loosely correlated with NGNE. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ZNTL jumps, then NGNE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZNTL
1D Price
Change %
ZNTL100%
+3.51%
NGNE - ZNTL
46%
Loosely correlated
-1.31%
FATE - ZNTL
44%
Loosely correlated
-2.71%
IDYA - ZNTL
44%
Loosely correlated
+0.27%
IMNM - ZNTL
43%
Loosely correlated
-4.39%
SYRE - ZNTL
43%
Loosely correlated
+1.07%
More